PARP inhibitor might benefit cancer patients with BRCA mutations

06/24/2009 | Forbes

Olaparib, a cancer drug that blocks a DNA-repair protein called Poly(ADP-ribose) polymerase, reduced tumor size in breast, ovarian and prostate cancer patients who carry BRCA1 and BRCA2 gene mutations, a Phase I study found. Few side effects appeared and those were managed by lowering dosage, researchers said.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations